Dexcom Inc. won an FDA de novo request for its Dexcom G6 continuous glucose monitoring (CGM) system, an upgrade from its prior G5 system, and one that eliminates the need for fingersticks. The device ...

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

DexCom, Inc.DXCM announced that its next generation G6 CGM system has received an approval from Health Canada, a regulatory authority. The device is designed to cater to diabetes patients in Canada, ...

Yesterday Dexcom got the nod from the FDA to market their Dexcom G6, an integrated continuous glucose monitoring system (iCGM), making it the first interoperable CGM to get the designation. “We are a ...

The Australian government has expanded the subsidised access to the latest generation of Dexcom's continuous glucose monitoring device, Dexcom G6, for diabetic Australians. This comes as the previous ...

First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, Dexcom, Inc.

The discovery that hydroxyurea interferes with the functioning of the Dexcom G6 continuous glucose monitor (CGM) in patients with diabetes came about from communication between one patient and one ...